Clinical Trials Browser

Interventional × Has results × Genistein × Clear all

Urinary Bladder Neoplasms

NCT02624388 2024-05-06

UVA-Gen001

Brain Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

NCT02567799 2024-01-25

NSCLC

Phase 1/2 Completed

21 enrolled 32 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00244933 2023-06-22

Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer

Phase 2 Completed

19 enrolled 5 charts

Breast

Breast Neoplasms

NCT02766478 2022-09-27

GeniPro

Phase 2 Terminated

10 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT00118040 2021-06-10

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Phase 2 Completed

60 enrolled 24 charts

Genitourinary

Urinary Bladder Neoplasms

NCT00376948 2021-03-01

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Completed

20 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00290758 2017-02-08

Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Phase 2 Completed

126 enrolled 16 charts

Breast

Breast Neoplasms

Clinical Trials

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

UVA-Gen001

NSCLC

Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer

GeniPro

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer